In the claims:

1. (**Currently Amended**) A method of administering to a subject in need thereof an effective amount of a cisplatin ~~**active agent**~~, said method comprising:

administering to said ~~**host**~~ **subject** ~~**said effective amount of a**~~ cisplatin ~~**active agent**~~ in conjunction with an amount of a ~~**cisplatin toxicity reducing agent**~~ **compound selected from TK-211; TK-295; TK-516; TK-523; TK-363; TK-204; TK-5145 and TK-5175** effective to reduce toxicity of said cisplatin ~~**active agent**~~.

2. (**Currently Amended**)The method according to Claim 1, wherein said cisplatin ~~**active agent**~~ and ~~**cisplatin toxicity reducing agent**~~ **said compound** are administered at the same time.

3. (**Currently Amended**)The method according to Claim 2, wherein said cisplatin ~~**active agent**~~ and ~~**cisplatin toxicity reducing agent**~~ **said compound** are administered as separate formulations.

4. (**Currently Amended**)The method according to Claim 2, wherein said cisplatin ~~**active agent**~~ and ~~**cisplatin toxicity reducing agent**~~ **said compound** are administered in a single formulation.

5. (**Currently Amended**)The method according to Claim 1, wherein said cisplatin ~~**active agent**~~ and ~~**cisplatin toxicity reducing agent**~~ **said compound** are administered sequentially.

6. (**Currently Amended**)The method according to Claim 5, wherein said cisplatin ~~**active agent**~~ is administered prior to said ~~**cisplatin toxicity reducing agent**~~ **compound**.

7. (**Currently Amended**) The method according to Claim 5, wherein said cisplatin ~~**active agent**~~ is administered after said ~~**cisplatin toxicity reducing agent**~~ **compound**.

8. (**Currently Amended**) The method according to Claim 1, wherein the amount of said ~~**cisplatin toxicity reducing agent**~~ **compound** is not more than about the amount of said cisplatin ~~**active agent**~~.

9.-16. (**CANCELLED**)

17. (**Currently Amended**) A method of treating ~~**a host suffering from a cellular proliferative disease condition**~~ **ovarian cancer in a patient**, said method comprising:

administering to said ~~**host**~~ **patient** ~~**said**~~ **an** ~~**effective**~~ amount of ~~**a cisplatin active agent**~~ **cisplatin effective to treat said cancer** in conjunction with an amount of ~~**a cisplatin toxicity reducing agent**~~ **TK-211** effective to reduce toxicity of said cisplatin ~~**active agent so that said host is treated for said cellular proliferative disease condition**~~.

18. (**Currently Amended**) The method according to Claim 17, wherein said cisplatin ~~**active agent**~~ and ~~**cisplatin toxicity reducing agent**~~ **said TK-211** are administered at the same time.

19. (**Currently Amended**) The method according to Claim 18, wherein said cisplatin ~~**active agent**~~ and ~~**cisplatin toxicity reducing agent**~~ **said TK-211** are administered as separate formulations.

20. (**Currently Amended**) The method according to Claim 18, wherein said cisplatin ~~**active agent**~~ and ~~**cisplatin toxicity reducing agent**~~ **said TK-211** are administered in a single formulation.

21. (**Currently Amended**) The method according to Claim 17, wherein said cisplatin ~~**active agent**~~ and ~~**cisplatin toxicity reducing agent**~~ **said TK-211** are administered sequentially.

22. (**Currently Amended**) The method according to Claim 21, wherein said cisplatin ~~**active agent**~~ is administered prior to said ~~**cisplatin toxicity reducing agent**~~ **TK-211**.

23. (**Currently Amended**) The method according to Claim 21, wherein said cisplatin ~~**active agent**~~ is administered after said ~~**cisplatin toxicity reducing agent**~~ **TK-211**.

24. (**Currently Amended**) The method according to Claim 17, wherein the amount of said ~~**cisplatin toxicity reducing agent**~~ **TK-211** is not more than about the amount of said cisplatin ~~**active agent**~~.

Claims 25 -30. (**CANCELLED**)